Compare Aurora Cannabis Inc (ACB) vs Invesco Ltd. (IVZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aurora Cannabis Inc vs Invesco Ltd. — how do they compare? Aurora Cannabis Inc trades at $2.7 (market cap $165.36M), while Invesco Ltd. trades at $27.06 (market cap $12.15B). The key difference: Invesco Ltd. is far larger — about 73.5× Aurora Cannabis Inc's market cap, and Invesco Ltd. pays a 3.14% dividend while Aurora Cannabis Inc pays none. Which is the better fit depends on your goals.
| ACB | IVZ | |
|---|---|---|
Market Cap | $165.36M | $12.15B |
Sector | Health | Financials |
52-Week High | $6.23 | $29.44 |
52-Week Low | $2.67 | $16.69 |
Enterprise Value | $99.82M | $22.39B |
Dividend Yield | — | 3.14% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aurora Cannabis Inc
Aurora Cannabis, based in Edmonton, Canada, grows and distributes both medical and recreational cannabis under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. While its main market is Canada, the company has also expanded globally through medical cannabis export agreements.
Read more on ACB →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
